Search results: 3
Your search "3" yielded 192 results. You are on page 1 out of 16.
With over 5,300 exhibitors from almost 70 countries MEDICA in Düsseldorf is one of the largest medical trade fairs in the world and one of the most important events we look forward to. This year, once again, we met our partners and collaborators, exchanged ideas, and discussed the latest developments. Our commitment to advancing healthcare technologies and enabling innovative diagnostics took center stage as we showcased our latest solutions!
A Platform for Innovation: Assay Development and Manufacturing Solutions for Diagnostics
We presented a suite of solutions designed to empower manufacturers in the diagnostics sector. From the instruments for precise dispensing of picoliters, nanoliters, and lower microliter volumes to flexible assay development and contract manufacturing services – our offerings aim to take bold product ideas to the market faster and easier.
- sciFLEXARRAYER SX – thanks to the camera installed inside of the instrument it was possible to watch the picoliter dispensing process on a big screen while getting a technology introduction from our Global Support and Service team
- sciFLEXARRAYER S3 NANO A/D – we presented a new multichannel configuration for aspirate-dispense nanoliter deposition without tedious calibration steps
- N-ABLE – a new “all in one box” concept of our modular and customizable high-throughput manufacturing solutions
Seminar Session: The Next Generation of Lateral Flow Assays in Multiplex Format
In recent years, multiplex lateral flow assays have become increasingly popular in disease management because they can rapidly analyze multiple parameters or biomarkers simultaneously. Common lateral flow test formats incorporate multiple lines or capture zones on the same test strip, each designed to detect a specific target molecule. There are limitations to these types of in-line tests, including false negatives, cross-reactivities, or high antibody consumption. During our seminar organized together with Sartorius, a complete solution including assay development with structured membranes, cassette use, and advanced LFA readout was showcased to the audience. We were happy to see the room filling up quickly and all available seats being taken! If you missed our seminar, you can find the white paper here.
Collaborative Networking: Get Together at SCIENION’s Booth
MEDICA provides an unparalleled opportunity for networking and collaboration so we organized a get-together event for our clients, partners, and friends. In a relaxed atmosphere, with tasty snacks and refreshing drinks, we enjoyed discussions around diagnostic sector trends, business plans, ambitious visions, and much more!
We would like to thank our community and all those who visited us at MEDICA 2023. Your support fuels our passion and propels us forward on our mission to enable the future of diagnostics!
The new platform broadens Cellenion’s single cell dispensing solutions portfolio by enabling the isolation and handling of cellular aggregates from 80 µm to 600 µm including spheroids, organoids, and tumoroids
Today, SCIENION & Cellenion, BICO companies, announced the launch of spheroONE, an innovative single large-particle sorter and dispenser which will revolutionize 3D cellular model handling. The platform is capable of dispensing individual spheroids, organoids, and tumoroids and complements Cellenion’s hugely successful cellenONE® platform for single cell isolation. The launch advances BICO’s Bio Convergence agenda by enabling easier use of complex in vitro 3D models that are more physiologically relevant, predictive and have the potential to complement and in some cases replace animal models in drug screening and other applications like cancer research.
“Current offerings suffer from low throughput, inconsistent sorting, and intensive manual dispensing,” explained Guilhem Tourniaire, PhD, Managing Director & Founder at Cellenion. “spheroONE is going to play a significant role toward replacing animal models in pre-clinical research as it allows automated sorting, enables development of higher quality and yield models, and improves outcome of 3D cell assays.”
spheroONE combines SCIENION’s sciDROP NANO precision dispensing technology with advanced image-based capabilities to enable precision isolation, sorting, and dispensing of single spheroids, organoids and tumoroids. The platform uses electromagnetic microvalve technology for gentle drop-on-demand generation in air which ensures maintenance of the integrity and viability of fragile cellular aggregates. Its combination of image-based capabilities, sorting and dispensing makes it the perfect platform for improving reproducibility of 3D model-based drug screens.
Other key features of spheroONE include:
- Up to 100% accurate automated isolation of single cellular aggregates using morphology and fluorescence-based sorting
- Controlled biomass via user-defined parameters (size and number of spheroids per well), facilitating high quality toxicological assays
- Streamlined drug screening on spheroids grown in bulk, reducing labor and enabling standardized 3D model-based assays
The spheroONE will broaden Cellenion’s customers’ ability to conduct vital life sciences research by enabling the handling of cellular aggregates ranging from 80 µm to 600 µm. The company’s cellenONE is already a reference in sorting and dispensing any cells from 0.5 – 80 µm with applications in single cell genomics, transcriptomics, proteomics, cell line development and rare cells.
Companies and organizations interested in the spheroONE can find more information at: www.cellenion.com/products/spheroone/
PR Contact
BICO Press office
Phone (US)
Riley Munks, PR Manager (650) 863-6699
Alyssa D’Orazio, PR Manager (617) 634-960
Email: [email protected]
About SCIENION
Founded in 2001, SCIENION is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is a complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services. The company operates from two sites in Germany, Dortmund and Berlin, and has subsidiaries in Arizona, USA; Chichester, UK; and Cellenion in Lyon, France.
SCIENION is part of BICO, the leading bio convergence company in the world that provides technologies, products and services to create the future of health.
About Cellenion
Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell and single cellular aggregates isolation. Our systems allow high throughput, image-based automated dispensing of single cells and/or cell aggregates onto any substrates of choice. Together with a range of dedicated consumables, the solutions enable miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volumes and outstanding recovery rates, Cellenion’s platforms offer unique capacities for applications including single-cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.
About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com